Endoscopic Variceal Ligation plus Octreotide versus Variceal Ligation Alone for the Prevention of Early Rebleeding from Esophageal Varices.
- Author:
Gyu Hyun LEE
;
Sung Won CHO
;
Heon Jong KIM
;
Kwang Hyun KO
;
Jun Ho KO
;
Young Yun KO
;
Ho Dong KIM
;
Kwang Jae LEE
;
Ki Baik HAHM
;
Jin Hong KIM
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Esophageal variceal bleeding;
Endoscopic variceal ligation;
Octreotide
- MeSH:
Endoscopy;
Esophageal and Gastric Varices*;
Hemorrhage;
Hospitalization;
Humans;
Hypertension, Portal;
Length of Stay;
Ligation*;
Mortality;
Octreotide*;
Varicose Veins
- From:The Korean Journal of Hepatology
1999;5(4):299-305
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Endoscopic variceal ligation (EVL) has been effective modality for esophageal variceal bleeding, but recurrent bleeding occurs 20 to 40% of patients. So there has been an increased interest in the use of vasoactive drugs to lower portal hypertension and help control variceal bleeding before and after endoscopy. We investigated the efficacy of octreotide (OCT) infusion as an adjunct to EVL for preventing early rebleeding from varices. METHODS: From Jan. 1997 to Feb. 1999, fifty four patients with endoscopically documented esophageal variceal bleeding were included. The patients were randomly treated by EVL alone (EVL group, n=30) or EVL plus octreotide (EVL+OCT group, n=24). We evaluated the 5-ay and 6-eek rebleeding rate and 6-eek mortality. RESULTS: Baseline characteristics were similar in two group but hospital stay (p=0.028) and units of transfused blood (p=0.043) were significantly less in EVL+OCT group. There were no significant differences on 5-ay rebleeding rate (EVL group; 7%, EVL+OCT group; 0%) and 6-eek rebleeding rate (EVL group; 20%, EVL+OCT group; 4%). CONCLUSIONS: The combined therapy did not decrease early rebleeding and mortality, but it was superior to EVL alone in hospital course such as requirement of transfusion and duration of hospitalization.
